Grace Therapeutics Inc (GRCE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.10-1.87%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — Achieve FDA approval for GTx-104: FDA approval not obtained; CRL received 2026-04-23 vs target 2026-Q4.
Grace aims to get FDA approval for GTx-104. Operating losses are shrinking from $4.8M to $3.0M. Cash burn is improving from negative $4.1M to negative $1.7M. These show progress in fixing the business.
FDA rejected their key drug in April 2026. A manufacturing setback threatens product launch. The company is still losing money and faces leadership changes.
The market is selling off sharply on the FDA rejection and manufacturing issues. There is no clear price or consensus growth data, so expectations are uncertain.
Breaks if: FDA approval not obtained by 2026-Q4
Breaks if: Major executive departures occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a high-risk scenario with a focus on potential recovery in the healthcare sector. The current thesis state is cautious, given recent earnings misses and ongoing operational losses.
The market appears to be pricing in a challenging environment, with expectations for continued losses and uncertainty around management's ability to execute on key priorities. The valuation reflects a loss-making status, indicating that investors are wary of future performance.
Fundamentals are likely to remain weak in the near term, with a high probability of an earnings miss due to erratic past performance. Management is focused on controlling cash burn and operational losses, but recent results show increasing net losses.
The thesis hinges on several factors, including the ability to achieve FDA approval for GTx-104 and the overall performance of the healthcare sector. Additionally, any cuts to guidance or continued weakness in economic indicators could negatively impact the stock.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company raised capital to extend its cash runway. This move supports ongoing operations and improves financial stability. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Ensure stability in leadership and executive team amid recent transitions.
Newly stated in 2026-Q2. Management disclosed a leadership change with the departure of the Vice President of Clinical Operations. No further details on broader leadership stability were provided. The priority is newly stated with limited information on follow-through.
Breaks if: Operating losses exceed -3.0 million USD by 2026-Q4
Control operating expenses and cash burn while advancing clinical and regulatory activities.
Stated as a priority in 4 of last 4 quarters. The company continues to manage operating losses and cash burn, with net losses increasing to $15.8 million in 2026-Q2 from $3.4 million in 2025-Q2, reflecting impairment charges. Operating income remains negative around $3 million per quarter. Cash used in operations was $3.2 million in 2026-Q2. The trajectory shows ongoing losses but management maintains focus on cost control.
“Cash used in operations was approximately $3.2 million; general and administrative expenses decreased by $0.4 million compared to prior year quarter.”
“Net loss of $7.8 million for fiscal year ended March 31, 2026, a $1.8 million decrease from prior year; research and development expenses decreased significantly.”
“Operating income was negative $3.18 million; net income positive $0.636 million.”
“Operating income negative $2.45 million; net income negative $2.32 million.”
Breaks if: Cash from operations worse than -1.7 million USD by 2026-Q4
Control operating expenses and cash burn while advancing clinical and regulatory activities.
Stated as a priority in 4 of last 4 quarters. The company continues to manage operating losses and cash burn, with net losses increasing to $15.8 million in 2026-Q2 from $3.4 million in 2025-Q2, reflecting impairment charges. Operating income remains negative around $3 million per quarter. Cash used in operations was $3.2 million in 2026-Q2. The trajectory shows ongoing losses but management maintains focus on cost control.
“Cash used in operations was approximately $3.2 million; general and administrative expenses decreased by $0.4 million compared to prior year quarter.”
“Net loss of $7.8 million for fiscal year ended March 31, 2026, a $1.8 million decrease from prior year; research and development expenses decreased significantly.”
“Operating income was negative $3.18 million; net income positive $0.636 million.”
“Operating income negative $2.45 million; net income negative $2.32 million.”
Over the next 1 to 3 years, GRCE's outlook is uncertain, heavily influenced by sector trends and management execution. Not investment advice.